Filterlex Medical Raises €7M to Revolutionize Embolic Protection

Filterlex Medical, a cardiovascular medical device startup based in Israel, has raised €7 million in equity investment to develop the next generation of embolic protection devices.

The equity investment came from the European Innovation Council Accelerator and will be part of Filterlex’s next round of financing, bringing the total funding raised by the startup so far to $19.3 million. The funding will boost the startup’s clinical program expansion, regulatory approvals, and the commercialization of its embolic protection devices. Sigal Eli, Founder and CEO, referred to the funding by stating:

“We are delighted to be selected to receive EIC funding for the second time. This EU validation will help us to further advance our technology and turn our vision into a reality to make the CAPTIS a best-in-class device for reducing the risk of stroke and other complications during catheter-based structural heart procedures such as TAVR.”

Filterlex was founded with the mission to create medical devices that reduced the risk of stroke and other complications resulting from heart procedures. The startup has experienced rapid growth following a $6 million Series A funding round in November of 2021. Over the past months, the startup has also started enrolling patients to participate in its first-in-human study for its CAPTIS full-body embolic protection system.

The EIC accelerator provides funding and investment to individual startups and small companies looking to develop “game-changing innovations”. Filterlex’s innovative approach has resulted in being one of the 99 companies chosen by the accelerator out of over 1000 companies. The selection process included companies from around 21 countries that applied to receive part of the €627 million available for funding, with the startup being one of only 19% of startups run by a female CEO.

According to the CDC, more than $60 Americans die as a result of embolism every year, with up to 30% dying between the first month after the diagnosis. Even when the patient survives, about one-half of them will experience long-term complications while one-third experience a recurrence over the next 10 years. By providing these patients with an embolic protection device, Filterlex can improve the lives of millions of patients around the world while also reducing the risks of recurrence.